Scholarlink

<p>Various <i>Clematis</i> species are well known for their therapeutic potential. Genus <i>Clematis</i> is source of phytochemically and pharmacologically diverse species. Extracts prepared from different parts such as leaves, stem, flowers, roots and rhizome have been reported to exert a range of pharmacological effects. Among these most of the exploited therapeutic activities are antioxidant, anti-inflammatory and anticancer. The present review article describes the various pharmacological activities, including analgesic, antiangiogenesis, antianxiety and antidepressant, antiarthritis, antibacterial, anticancer, antifungal, antihyperuricemic, anti-inflammatory, antioxidant, antiulcerogenic, antivenom, antiviral, atherosclerosis, cardioprotective, hepatoprotective, insecticidal etc. This comprehensive review aims to provide an overview of the traditional use and phytochemical composition of <i>Clematis</i> species as well as the very recent bioactivities of secondary metabolites derived from these species. Recent in vitro<i>, </i>in vivo, and preclinical studies are reviewed and discussed, particularly focusing on cytotoxic, antidiabetic, antibacterial, anti-inflammatory, antioxidant, antifungal and cardioprotective activities. Furthermore, the anticancer potential of various <i>Clematis</i> species extracts and isolated constituents are also described. The effects of major <i>Clematis</i> species compounds on detailed anticancer mechanism have been widely studied. Therefore, the ability of <i>Clematis</i> species compounds to function as anticancer drugs in the context of cancer drug discovery has become a promising area of investigation. The existing body of evidence indicates that <i>Clematis</i> species possess significant potential to be developed into clinically effective therapeutic agents. While several secondary metabolites have shown promising activity in the in vitro studies, comprehensive in vivo investigations and clinical trials are crucial to validate these findings and identify novel drug. Therefore, it is imperative that <i>Clematis</i> species undergo rigrous and systematic research, particularly at the clinical level, to facilitate the development of safer and more efficacious medicinal products.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

An update on different phytoconstituents and pharmacological potential of Clematis species: a review

  • 期刊论文

  • 发表日期：

    2026年6月24日

查看全文
  • Reena Jassal,
  • Preeti Kheterpal,
  • Suresh Kumar

摘要

Various Clematis species are well known for their therapeutic potential. Genus Clematis is source of phytochemically and pharmacologically diverse species. Extracts prepared from different parts such as leaves, stem, flowers, roots and rhizome have been reported to exert a range of pharmacological effects. Among these most of the exploited therapeutic activities are antioxidant, anti-inflammatory and anticancer. The present review article describes the various pharmacological activities, including analgesic, antiangiogenesis, antianxiety and antidepressant, antiarthritis, antibacterial, anticancer, antifungal, antihyperuricemic, anti-inflammatory, antioxidant, antiulcerogenic, antivenom, antiviral, atherosclerosis, cardioprotective, hepatoprotective, insecticidal etc. This comprehensive review aims to provide an overview of the traditional use and phytochemical composition of Clematis species as well as the very recent bioactivities of secondary metabolites derived from these species. Recent in vitro, in vivo, and preclinical studies are reviewed and discussed, particularly focusing on cytotoxic, antidiabetic, antibacterial, anti-inflammatory, antioxidant, antifungal and cardioprotective activities. Furthermore, the anticancer potential of various Clematis species extracts and isolated constituents are also described. The effects of major Clematis species compounds on detailed anticancer mechanism have been widely studied. Therefore, the ability of Clematis species compounds to function as anticancer drugs in the context of cancer drug discovery has become a promising area of investigation. The existing body of evidence indicates that Clematis species possess significant potential to be developed into clinically effective therapeutic agents. While several secondary metabolites have shown promising activity in the in vitro studies, comprehensive in vivo investigations and clinical trials are crucial to validate these findings and identify novel drug. Therefore, it is imperative that Clematis species undergo rigrous and systematic research, particularly at the clinical level, to facilitate the development of safer and more efficacious medicinal products.